Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-10

Name: Phase 3 Topline: A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-10
Start: 2029-07-01

July 1, 2029

Company: PureTech Health plc (PRTC)
Drug: idiopathic
Indication: Idiopathic Pulmonary Fibrosis (IPF)

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-10 — PRTC Phase 3 Readout | BioSniper